Today it was reported that the President & CEO of Five Prime Therapeutics (NASDAQ: FPRX), Aron Marc Knickerbocker, exercised options to buy 500 FPRX shares at $11.14 a share, for a total transaction value of $5,570.
See today’s analyst top recommended stocks >>
Currently, Five Prime Therapeutics has an average volume of 324.8K.
Nine different firms, including BMO Capital and Citigroup, currently also have a Buy rating on the stock.
The insider sentiment on Five Prime Therapeutics has been positive according to 29 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Aron Marc Knickerbocker’s trades have generated a 62.0% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. product candidates includes, Cabiralizumab(FPA008), Bemarituzumab(FPA144), and FPA150.
